Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis of IFF stock:

Technical Analysis

• Current price: $79.82 (as of regular market trading on 2025-02-24)
• The stock is showing bearish momentum, having declined from recent highs around $81-82
• RSI (14) at 32.01 indicates oversold conditions
• Trading below all major moving averages (5,10,20,60,200-day SMAs)

Fundamental Analysis

• Revenue declined from $12.44B (2022) to $11.48B (2023)
• Net losses widened from -$1.87B (2022) to -$2.57B (2023)
• Gross margin deteriorated from 27.52% to 26.14%
• Current ratio declined from 1.99 to 1.67, indicating weaker liquidity

Recent Developments

• CFRA recently double-downgraded the stock to sell from buy
• Company scheduled to release Q4 & FY2024 results on February 18, 2025
• Plans to divest pharma solutions segment by H1 2025

Business Segments Performance

• Nourish (52.8%): $6.06B revenue, declining from $6.83B
• Scent (20.8%): $2.39B revenue, growing from $2.30B
• Health & Biosciences (18.1%): $2.08B revenue, declining from $2.34B
• Pharma Solutions (8.2%): $945M revenue, declining from $971M

Recommendation: SELL

• Technical indicators show bearish momentum
• Fundamental deterioration across key metrics
• Segment performance showing weakness in core businesses
• Recent analyst downgrades reflect negative sentiment
• Support levels at $78.27 (Fibonacci S2) with resistance at $80.17 (Fibonacci S1)

Based on the provided data and context, here is my analysis for IFF's stock price prediction in 2025:

Technical Analysis

The stock is currently showing bearish momentum with RSI at 32.01 indicating oversold conditions. The stock has broken below key support levels and is trading well below both 50-day and 200-day moving averages, suggesting sustained downward pressure.

Fundamental Drivers

• Q4 2024 Results: IFF reported full year sales of $11.48 billion with currency neutral growth of 6%, driven by strong performance in Scent division
• 2025 Guidance:
  • Sales: $10.6-10.9 billion
  • Adjusted EBITDA: $2.0-2.15 billion
  • Comparable currency neutral sales growth: 1-4%
  • Note: Guidance includes only 6 months of Pharma Solutions due to planned divestiture

Price Target Analysis

According to analyst consensus:

• Average price target: $103.50 (29.62% upside from current $79.85)
• Range: $77.00 - $120.00
• Rating: Moderate Buy (12 Buy, 2 Hold, 2 Sell ratings)

2025 Price Prediction

Based on technical and fundamental factors, I predict three scenarios for IFF stock in 2025:

1. Base Case (60% probability): $85-90

• Modest recovery as cost savings initiatives take hold
• Successful completion of Pharma Solutions divestiture
• Stabilizing margins in core business

2. Bull Case (20% probability): $95-105

• Stronger than expected sales growth
• Margin expansion exceeding guidance
• Positive sentiment shift from institutional investors

3. Bear Case (20% probability): $70-75

• Continued margin pressure
• Integration challenges
• Broader market volatility impacting multiples

Conclusion

The most likely scenario points to IFF trading in the $85-90 range by end of 2025, representing ~10% upside from current levels. Key catalysts will be successful execution of strategic initiatives and margin improvement.

The S1 support level for IFF Stock is $79.72 ,The R1 resistant level for IFF Stock is $85.87.

As of the end of day on 2025-02-27, the price of IFF Stock was $81.24.

The target price for IFF Stock according to analyst rating is 97.08, with the highest price target at 106.00 and the lowest at 77.00. Analysts have a Moderate Buy rating on IFF Stock overall.

The market cap of IFF is $20.6B.

Based on the financial data and market indicators, IFF appears to be undervalued at current levels. The company's EV/EBITDA multiple of 17.49x shows deterioration in operational efficiency, with net margins declining significantly from -14.98% to -22.33% year-over-year. Technical indicators suggest oversold conditions with RSI at 32.01 and trading below all major moving averages, particularly the 200-day SMA at $94.38. The stock's current price of $79.82 represents a significant discount to its intrinsic value, considering the company's market leadership position in flavors and fragrances despite recent operational challenges. The upcoming Q4 2024 earnings release on February 18, 2025 could serve as a potential catalyst for price recovery.

International Flavors & Fragrances Inc. is a creator and manufacturer of food, beverage, health and biosciences, scent and pharma solutions and complementary adjacent products. The Company operates through four segments. Nourish segment consists of a portfolio of natural-based ingredients to enhance nutritional value, texture and functionality in a range of beverage, dairy, bakery, confectionery and culinary applications and consists of ingredients, flavors and food designs. Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Scent segment creates fragrance compounds, fragrance ingredients and cosmetic ingredients. Pharma Solutions segment produces a portfolio that includes cellulosics and seaweed-based pharmaceutical excipients, used to improve the functionality and delivery of active pharmaceutical ingredients.

Based on the provided data and context, I'll analyze IFF's potential price for 2030:

IFF stock is projected to reach approximately $145-155 by 2030, driven by its strategic position in flavors and fragrances market and ongoing business transformation initiatives. The company's focus on sustainable innovations and market leadership in specialized ingredients should support long-term growth despite current market challenges.

IFF has a total of 21500 employees.